Last Posted: Dec 19, 2018
- Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Solomon Haley V et al. Psychiatry research 2018 Dec 271604-613 - Polygenic risk score identifies associations between sleep duration and diseases determined from an electronic medical record biobank.
Dashti Hassan S et al. Sleep 2018 Dec - Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
Bousman Chad A et al. Pharmacogenomics 2019 Jan 20(1) 37-47 - A Pharmacogenomic-based Antidepressant Treatment for Patients with Major Depressive Disorder: Results from an 8-week, Randomized, Single-blinded Clinical Trial.
Han Changsu et al. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology 2018 Nov 16(4) 469-480 - Statistical pitfalls of personalized medicine
S Senn, Nature News, November 27, 2018 - Preferences for in-person disclosure: Patients declining telephone disclosure characteristics and outcomes in the multi-center COGENT Study.
Beri Nina et al. Clinical genetics 2018 Nov - Genetics of response to cognitive behavior therapy in adults with major depression: a preliminary report.
Andersson Evelyn et al. Molecular psychiatry 2018 Nov - Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.
Chang Donald D et al. Pharmacogenomics 2018 Nov 19(16) 1269-1284 - Using genetics to understand the causal influence of higher BMI on depression.
Tyrrell Jessica et al. International journal of epidemiology 2018 Nov - Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
Groessl Erik J et al. Journal of managed care & specialty pharmacy 2018 Aug 24(8) 726-734
.png)
No hay comentarios:
Publicar un comentario